gliclazide has been researched along with pioglitazone in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (63.16) | 29.6817 |
| 2010's | 13 (34.21) | 24.3611 |
| 2020's | 1 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Kubo, K | 1 |
| Lawrence, JM; Reckless, JP; Reid, J; Stirling, C; Taylor, GJ | 1 |
| Araki, A; Sasamoto, K; Shirabe, S; Yamanouchi, T; Yanagawa, T | 1 |
| Campbell, IW | 1 |
| Belcher, G; Edwards, G; Goh, KL; Lambert, C; Valbuena, M | 1 |
| Edwards, G; Khan, M; Mariz, S; Urquhart, R; Xu, Y | 1 |
| Baksi, A; Edwards, G; Johns, D; Krahulec, B; Kubalski, P; Stankiewicz, A; Tan, MH; Urquhart, R | 1 |
| Charbonnel, B; Johns, D; Mariz, S; Mihm, M; Roden, M; Tan, M; Urquhart, R; Widel, M | 1 |
| Brunetti, P; Charbonnel, BH; Hanefeld, M; Matthews, DR; Schernthaner, G | 1 |
| Brunetti, P; Charbonnel, B; Hanefeld, M; Matthews, DR; Schernthaner, G; Tan, MH; Urquhart, R | 1 |
| Schumm-Draeger, PM | 1 |
| Belcher, G; Edwards, G; Lambert, C; Matthews, DR; Urquhart, R | 1 |
| Belcher, G; Schernthaner, G | 1 |
| Betteridge, DJ; Vergès, B | 1 |
| Brunetti, P; Di Pietro, C; Pampanelli, S; Perriello, G | 1 |
| Choudhury, H; Harisudhan, T; Mullangi, R; Srinivas, NR; Venkatesh, P | 1 |
| Danhof, M; de Winter, W; DeJongh, J; Eckland, D; Moules, I; Ploeger, B; Post, T; Urquhart, R | 1 |
| Brunetti, P; di Pietro, C; Mariz, S; Pampanelli, S; Perriello, G | 1 |
| Alagona, C; Chiavetta, A; Fedele, V; Leotta, C; Lorenti, I; Luca, S; Papa, G; Pezzino, V; Piro, S; Purrello, F; Rabuazzo, AM; Spadaro, L | 1 |
| Gallen, IW; Lumb, AN | 1 |
| Brazzale, AR; Mariz, S; Pacini, G; Roden, M | 1 |
| Ben Salem, C; Biour, M; Slim, R; Zami, M; Zamy, M | 1 |
| Chen, Y; Hu, YY; Wu, FZ; Ye, SD; Zhao, LL; Zheng, M | 1 |
| Al-Azzam, SI; Almahasneh, FA; Alomari, M; Altawalbeh, S; Khader, YS; Muflih, SM | 1 |
| Jermendy, G | 1 |
| Agrawal, N; Bhandari, S; Chandurkar, N; Deshpande, A; Devaramani, S; Gupta, OP; Kakrani, A; Kothari, K; Mahesh, M; Pareek, A; Saboo, B; Shah, A; Sharma, S; Thomas, N; Thulasidharan, NK; Vijaykumar, NB; Viswanathan, V | 1 |
| Civan, N; Deger, O; Erem, C; Ersoz, HO; Nuhoglu, I; Ozbas, HM | 1 |
| Chowdhury, TA; Fan, SL; Oei, E; Samad, N; Visser, A | 1 |
| García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G | 1 |
| Bhutani, R; Bodla, RB; Kant, R; Kapoor, G | 1 |
| Fu, BY; Wang, XJ | 1 |
5 review(s) available for gliclazide and pioglitazone
| Article | Year |
|---|---|
Long-term glycaemic control with pioglitazone in patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Randomized Controlled Trials as Topic; Thiazolidinediones; Treatment Outcome | 2004 |
Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Gliclazide; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Randomized Controlled Trials as Topic; Stroke; Thiazolidinediones | 2004 |
Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2005 |
[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Gliclazide; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors | 2005 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
17 trial(s) available for gliclazide and pioglitazone
| Article | Year |
|---|---|
Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metformin; Middle Aged; Obesity; Pioglitazone; Thiazolidinediones; Triglycerides | 2004 |
Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Blood Glucose; Cholesterol; Creatinine; Deoxyglucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Thiazolidinediones | 2004 |
Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Gliclazide; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Prospective Studies; Thiazolidinediones; Treatment Outcome; Triglycerides | 2004 |
Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Thiazolidinediones; Time Factors; Treatment Failure | 2005 |
Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2005 |
A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Gliclazide; Humans; Hypoglycemic Agents; Insulin; Lipids; Middle Aged; Pioglitazone; Proinsulin; Thiazolidinediones; Treatment Outcome | 2005 |
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Reproducibility of Results; Safety; Thiazolidinediones; Treatment Failure; Treatment Outcome | 2005 |
Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; gamma-Glutamyltransferase; Gliclazide; Glycated Hemoglobin; Hematocrit; Humans; Hypoglycemic Agents; Leukocyte Count; Male; Metformin; Middle Aged; Pioglitazone; Platelet Count; Thiazolidinediones | 2005 |
Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver Diseases; Liver Extracts; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2005 |
Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Gliclazide; Humans; Hypoglycemic Agents; Lipids; Lipoproteins; Metformin; Middle Aged; Pioglitazone; Risk Factors; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Triglycerides | 2005 |
Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Long-Term Care; Male; Middle Aged; Pioglitazone; Thiazolidinediones | 2006 |
Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Coagulation Factors; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Male; Middle Aged; Pioglitazone; Thiazolidinediones; Time Factors; Treatment Outcome | 2007 |
Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs.
Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Carbamates; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pioglitazone; Piperidines; Research Design; Rosiglitazone; Thiazolidinediones | 2008 |
Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Gliclazide; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes.
Topics: Adult; Albuminuria; Blood Glucose; Blood Pressure; Chemokine CCL2; Creatinine; Cytokines; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Gliclazide; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2010 |
Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hydroxychloroquine; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Young Adult | 2014 |
Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus.
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Risk Factors; Thiazolidinediones | 2014 |
17 other study(ies) available for gliclazide and pioglitazone
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Gliclazide; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Pioglitazone; Proinsulin; Thiazoles; Thiazolidinediones | 2002 |
[Long-term HbA1c stable. Insulin sensitizer keeps diabetes in check].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Randomized Controlled Trials as Topic; Thiazolidinediones; Treatment Outcome | 2004 |
[2-year data of large clinical comparative studies. Type 2 diabetes: lasting metabolic control with pioglitazone].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Mice; Pioglitazone; Thiazolidinediones; Time Factors | 2004 |
Simultaneous estimation of six anti-diabetic drugs--glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human p
Topics: Carbamates; Chromatography, High Pressure Liquid; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Molecular Structure; Pioglitazone; Piperidines; Reproducibility of Results; Rosiglitazone; Thiazolidinediones | 2006 |
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Algorithms; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Models, Biological; Multicenter Studies as Topic; Pioglitazone; Randomized Controlled Trials as Topic; Thiazolidinediones; Treatment Outcome | 2006 |
Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Hepatocyte Nuclear Factor 1-alpha; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazone; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2009 |
Pioglitazone-induced acute rhabdomyolysis.
Topics: Acute Disease; Aged; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Male; Muscle, Skeletal; Pioglitazone; Probability; Rhabdomyolysis; Thiazolidinediones | 2009 |
Effects of pioglitazone add-on to gliclazide and metformin on glycemic control in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Retrospective Studies; Thiazolidinediones | 2012 |
Use of continuous glucose monitoring in patients with diabetes on peritoneal dialysis: poor correlation with HbA1c and high incidence of hypoglycaemia.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin; Kidney Failure, Chronic; Male; Middle Aged; Monitoring, Ambulatory; Peritoneal Dialysis, Continuous Ambulatory; Pioglitazone; Thiazolidinediones | 2016 |
Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Lipids; Liraglutide; Liver Function Tests; Male; Metabolic Syndrome; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Peptides; Pilot Projects; Pioglitazone; Prospective Studies; Sitagliptin Phosphate; Thiazolidinediones; Venoms; Waist Circumference | 2016 |
Optimization of a single HPLC-PDA method for quantifying Metformin, Gliclazide, Pioglitazone, Dapagliflozin, Empagliflozin, Saxagliptin, Linagliptin and Teneligliptin using central composite design.
Topics: Adamantane; Benzhydryl Compounds; Chromatography, High Pressure Liquid; Dipeptides; Dose-Response Relationship, Drug; Gliclazide; Glucosides; Linagliptin; Metformin; Molecular Structure; Pioglitazone; Pyrazoles; Software; Structure-Activity Relationship; Thiazolidines | 2019 |
The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases.
Topics: Diabetes Mellitus, Type 2; Exenatide; Gliclazide; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Sitagliptin Phosphate | 2022 |